文献速递贫血与红细胞疾病白血病

可检测的血液克隆嵌合体作为范可尼贫血癌症风险的生物标志物

Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia.
PubMed 文献 · Blood Adv · 2017-01-23

研究对130例范可尼贫血(FA)患者血液DNA行SNP阵列检测克隆嵌合事件(CME),16例(12.3%)检出51个CME,以3q和1q获得及主要组织相容性复合体位点断裂点聚集最常见。CME携带者血液肿瘤和实体瘤风险升高(OR=11.6,95%CI=3.4-39.3),死亡风险升高(HR=4.0,95%CI=2.0-7.9)。

要点

  • 130例FA患者中16例(12.3%)血液检出CME,9例有多个CME。
  • CME以3q获得(n=6)和1q获得(n=5)最常见,均与白血病相关。
  • CME携带者癌症风险升高(OR=11.6,95%CI=3.4-39.3),死亡风险升高(HR=4.0,95%CI=2.0-7.9)。

核心结论

  • FA患者血液中可检测的CME发生率较高,且与血液肿瘤和实体瘤风险及较差预后相关。
  • 作者认为用易获取的血液样本行SNP阵列分子核型分析,或可用于更好地监测FA患者骨髓克隆事件、癌症风险和总生存。

研究设计与样本

  • 研究采用SNP阵列检测130例FA患者血液DNA中的CME,并与15743例年龄匹配人群对照比较。

主要发现

  • 130例FA患者中16例(12.3%)检出51个CME,大小4.4-159 Mb,其中9例有多个CME。
  • 最常见事件为3q获得(n=6)和1q获得(n=5),两者既往均与白血病相关;另见断裂点聚集于主要组织相容性复合体位点的重排(P=7.3×10-9)。
  • 与15743例年龄匹配人群对照相比,FA患者血液可检测CME的风险高126至140倍(P<2.2×10-16)。
  • CME携带者中流行性和新发血液肿瘤及实体瘤更常见(OR=11.6,95%CI=3.4-39.3,P=2.8×10-5),导致预后更差。
  • 有CME的FA个体发生癌症的年龄调整风险比(HR)几乎是无CME者的5倍;有CME的FA个体死亡HR为4.0(95%CI=2.0-7.9,P=5.7×10-5)。

临床怎么用

  • 作者认为,用易获取的血液样本行SNP阵列分子核型分析,或可用于更好地监测FA患者的骨髓克隆事件、癌症风险和总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 × 10-9). Compared with 15 743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 × 10-16). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 × 10-5), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 × 10-5). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Reina-Castillón J, Pujol R, López-Sánchez M, et al. Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. Blood Adv. 2017. PMID: 29296947. doi:10.1182/bloodadvances.2016000943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。